Relieves bronchospasm. ANDA 215571, held by LEXENPHARM. Albuterol Sulfate.
As of Nov 18, 2026, ANDA 215571 (Albuterol Sulfate), held by LEXENPHARM, was first approved by FDA on May 3, 2024, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Albuterol sulfate inhalation solution is indicated for the relief of bronchospasm in patients 2 to 12 years of age with asthma (reversible obstructive airway disease).
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 3, 2024 | Original application | Approved | None posted |
| Albuterol SulfateEQ 0.021% BASE · solution;inhalation | Albuterol Sulfate | Rx |
| Albuterol SulfateEQ 0.042% BASE · solution;inhalation | Albuterol Sulfate | Rx |
| Sep 16, 2026 | Supplement 6Manufacturing | Approved | None posted |
| May 3, 2024 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters